University of California, Davis, Division of Rheumatology, Allergy and Clinical Immunology, Genome and Biomedical Sciences Facility, 451 East Health Sciences Drive, Davis, CA 95616, USA.
Autoimmun Rev. 2010 Mar;9(5):A342-9. doi: 10.1016/j.autrev.2009.11.020. Epub 2009 Nov 27.
First described in 1735 (Watson-Williams et al., 1958), immune-mediated platelet destruction is a phenomenon of protean associations that has historically varied in its definition. Recently, consensus guidelines were proposed for a standardized system of nomenclature that preserves the acronym "ITP" but encompasses a number of causes of immune-mediated thrombocytopenias, including both primary immune thrombocytopenia as well as such entities as thrombocytopenia associated with connective tissue diseases or cancer. In this paper, we will focus on current aspects of geoepidemiology, pathophysiology, diagnosis and management of adult and pediatric primary immune thrombocytopenia. It is clear that both genetic and extrinsic factors exist for ITP and are likely different between children and adults. Immune thrombocytopenia remains a challenging problem but our understanding of its pathophysiology has greatly improved.
首例于 1735 年被描述（Watson-Williams 等人，1958 年），免疫介导的血小板破坏是一种具有多种关联的现象，其定义在历史上有所不同。最近，提出了共识指南，以建立标准化命名系统，保留缩写“ITP”，但包括多种免疫介导的血小板减少症的原因，包括原发性免疫性血小板减少症以及与结缔组织疾病或癌症相关的实体。在本文中，我们将重点关注成人和儿科原发性免疫性血小板减少症的地理流行病学、病理生理学、诊断和治疗的当前方面。显然，ITP 存在遗传和外在因素，并且在儿童和成人之间可能不同。免疫性血小板减少症仍然是一个具有挑战性的问题，但我们对其病理生理学的理解有了很大的提高。
